世界のプロタンパク質転換酵素サブチリシン/ケキシン9型市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5965 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、123ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥585,000 (USD3,900)	▷ お問い合わせ
Multi User	￥877,500 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、プロタンパク質転換酵素サブチリシン/ケキシン9型の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（SX-PCK9、O-304、K-312、BLSM-201、DCRPCSK-9、その他）、用途別市場規模（心血管疾患、同種家族性高コレステロール血症、肝疾患、メタボリックシンドローム、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・プロタンパク質転換酵素サブチリシン/ケキシン9型の市場動向 ・企業の競争状況、市場シェア ・プロタンパク質転換酵素サブチリシン/ケキシン9型の種類別市場規模と予測2016-2027（SX-PCK9、O-304、K-312、BLSM-201、DCRPCSK-9、その他） ・プロタンパク質転換酵素サブチリシン/ケキシン9型の用途別市場規模と予測2016-2027（心血管疾患、同種家族性高コレステロール血症、肝疾患、メタボリックシンドローム、その他） ・プロタンパク質転換酵素サブチリシン/ケキシン9型の北米市場規模2016-2027（アメリカ、カナダ） ・プロタンパク質転換酵素サブチリシン/ケキシン9型の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・プロタンパク質転換酵素サブチリシン/ケキシン9型のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・プロタンパク質転換酵素サブチリシン/ケキシン9型の中南米市場規模2016-2027（メキシコ、ブラジル） ・プロタンパク質転換酵素サブチリシン/ケキシン9型の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AFFiRiS AG、Betagenon AB、Bioleaders Corp、BioLingus AG、Catabasis Pharmaceuticals Inc、Dicerna Pharmaceuticals Inc、Eli Lilly and Co、Ensemble Therapeutics Corp、Kowa Co Ltd、Novartis AG、Pfizer Inc、Regeneron Pharmaceuticals Inc、Serometrix LLC、Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd、The Medicines Company） ・結論

Market Analysis and Insights: Global Proprotein Convertase Subtilisin/Kexin Type 9 Market
The global Proprotein Convertase Subtilisin/Kexin Type 9 market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Proprotein Convertase Subtilisin/Kexin Type 9 market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Proprotein Convertase Subtilisin/Kexin Type 9 market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Proprotein Convertase Subtilisin/Kexin Type 9 market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Proprotein Convertase Subtilisin/Kexin Type 9 market.

Global Proprotein Convertase Subtilisin/Kexin Type 9 Scope and Market Size
Proprotein Convertase Subtilisin/Kexin Type 9 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Proprotein Convertase Subtilisin/Kexin Type 9 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
SX-PCK9
O-304
K-312
BLSM-201
DCRPCSK-9
Others

Segment by Application
Cardiovascular Disease
Homozugous Familial Hyperchalesterolemia
Liver Disease
Metabolic Syndrome
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AFFiRiS AG
Betagenon AB
Bioleaders Corp
BioLingus AG
Catabasis Pharmaceuticals Inc
Dicerna Pharmaceuticals Inc
Eli Lilly and Co
Ensemble Therapeutics Corp
Kowa Co Ltd
Novartis AG
Pfizer Inc
Regeneron Pharmaceuticals Inc
Serometrix LLC
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
The Medicines Company

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 SX-PCK9
1.2.3 O-304
1.2.4 K-312
1.2.5 BLSM-201
1.2.6 DCRPCSK-9
1.2.7 Others
1.3 Market by Application
1.3.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Cardiovascular Disease
1.3.3 Homozugous Familial Hyperchalesterolemia
1.3.4 Liver Disease
1.3.5 Metabolic Syndrome
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Perspective (2016-2027)
2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Growth Trends by Regions
2.2.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Proprotein Convertase Subtilisin/Kexin Type 9 Historic Market Share by Regions (2016-2021)
2.2.3 Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Regions (2022-2027)
2.3 Proprotein Convertase Subtilisin/Kexin Type 9 Industry Dynamic
2.3.1 Proprotein Convertase Subtilisin/Kexin Type 9 Market Trends
2.3.2 Proprotein Convertase Subtilisin/Kexin Type 9 Market Drivers
2.3.3 Proprotein Convertase Subtilisin/Kexin Type 9 Market Challenges
2.3.4 Proprotein Convertase Subtilisin/Kexin Type 9 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Revenue
3.1.1 Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Revenue (2016-2021)
3.1.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Players (2016-2021)
3.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue
3.4 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Concentration Ratio
3.4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue in 2020
3.5 Proprotein Convertase Subtilisin/Kexin Type 9 Key Players Head office and Area Served
3.6 Key Players Proprotein Convertase Subtilisin/Kexin Type 9 Product Solution and Service
3.7 Date of Enter into Proprotein Convertase Subtilisin/Kexin Type 9 Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Type
4.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Historic Market Size by Type (2016-2021)
4.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Type (2022-2027)

5 Proprotein Convertase Subtilisin/Kexin Type 9 Breakdown Data by Application
5.1 Global Proprotein Convertase Subtilisin/Kexin Type 9 Historic Market Size by Application (2016-2021)
5.2 Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027)
6.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type
6.2.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021)
6.2.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027)
6.2.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027)
6.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application
6.3.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021)
6.3.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027)
6.3.3 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027)
6.4 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
6.4.1 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021)
6.4.2 North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027)
7.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type
7.2.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021)
7.2.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027)
7.2.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027)
7.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application
7.3.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021)
7.3.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027)
7.3.3 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027)
7.4 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
7.4.1 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021)
7.4.2 Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027)
8.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type
8.2.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027)
8.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application
8.3.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027)
8.4 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region
8.4.1 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027)
9.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type
9.2.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021)
9.2.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027)
9.2.3 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027)
9.3 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application
9.3.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021)
9.3.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027)
9.3.3 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027)
9.4 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
9.4.1 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021)
9.4.2 Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (2016-2027)
10.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type
10.2.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2027)
10.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application
10.3.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2027)
10.4 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country
10.4.1 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AFFiRiS AG
11.1.1 AFFiRiS AG Company Details
11.1.2 AFFiRiS AG Business Overview
11.1.3 AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.1.4 AFFiRiS AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.1.5 AFFiRiS AG Recent Development
11.2 Betagenon AB
11.2.1 Betagenon AB Company Details
11.2.2 Betagenon AB Business Overview
11.2.3 Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.2.4 Betagenon AB Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.2.5 Betagenon AB Recent Development
11.3 Bioleaders Corp
11.3.1 Bioleaders Corp Company Details
11.3.2 Bioleaders Corp Business Overview
11.3.3 Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.3.4 Bioleaders Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.3.5 Bioleaders Corp Recent Development
11.4 BioLingus AG
11.4.1 BioLingus AG Company Details
11.4.2 BioLingus AG Business Overview
11.4.3 BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.4.4 BioLingus AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.4.5 BioLingus AG Recent Development
11.5 Catabasis Pharmaceuticals Inc
11.5.1 Catabasis Pharmaceuticals Inc Company Details
11.5.2 Catabasis Pharmaceuticals Inc Business Overview
11.5.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.5.4 Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.5.5 Catabasis Pharmaceuticals Inc Recent Development
11.6 Dicerna Pharmaceuticals Inc
11.6.1 Dicerna Pharmaceuticals Inc Company Details
11.6.2 Dicerna Pharmaceuticals Inc Business Overview
11.6.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.6.4 Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.6.5 Dicerna Pharmaceuticals Inc Recent Development
11.7 Eli Lilly and Co
11.7.1 Eli Lilly and Co Company Details
11.7.2 Eli Lilly and Co Business Overview
11.7.3 Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.7.4 Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.7.5 Eli Lilly and Co Recent Development
11.8 Ensemble Therapeutics Corp
11.8.1 Ensemble Therapeutics Corp Company Details
11.8.2 Ensemble Therapeutics Corp Business Overview
11.8.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.8.4 Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.8.5 Ensemble Therapeutics Corp Recent Development
11.9 Kowa Co Ltd
11.9.1 Kowa Co Ltd Company Details
11.9.2 Kowa Co Ltd Business Overview
11.9.3 Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.9.4 Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.9.5 Kowa Co Ltd Recent Development
11.10 Novartis AG
11.10.1 Novartis AG Company Details
11.10.2 Novartis AG Business Overview
11.10.3 Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.10.4 Novartis AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.10.5 Novartis AG Recent Development
11.11 Pfizer Inc
11.11.1 Pfizer Inc Company Details
11.11.2 Pfizer Inc Business Overview
11.11.3 Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.11.4 Pfizer Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.11.5 Pfizer Inc Recent Development
11.12 Regeneron Pharmaceuticals Inc
11.12.1 Regeneron Pharmaceuticals Inc Company Details
11.12.2 Regeneron Pharmaceuticals Inc Business Overview
11.12.3 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.12.4 Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.12.5 Regeneron Pharmaceuticals Inc Recent Development
11.13 Serometrix LLC
11.13.1 Serometrix LLC Company Details
11.13.2 Serometrix LLC Business Overview
11.13.3 Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.13.4 Serometrix LLC Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.13.5 Serometrix LLC Recent Development
11.14 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
11.14.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Details
11.14.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
11.14.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.14.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.14.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development
11.15 The Medicines Company
11.15.1 The Medicines Company Company Details
11.15.2 The Medicines Company Business Overview
11.15.3 The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Introduction
11.15.4 The Medicines Company Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
11.15.5 The Medicines Company Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of SX-PCK9
Table 3. Key Players of O-304
Table 4. Key Players of K-312
Table 5. Key Players of BLSM-201
Table 6. Key Players of DCRPCSK-9
Table 7. Key Players of Others
Table 8. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 10. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Regions (2016-2021) & (US$ Million)
Table 11. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions (2016-2021)
Table 12. Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 13. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions (2022-2027)
Table 14. Proprotein Convertase Subtilisin/Kexin Type 9 Market Trends
Table 15. Proprotein Convertase Subtilisin/Kexin Type 9 Market Drivers
Table 16. Proprotein Convertase Subtilisin/Kexin Type 9 Market Challenges
Table 17. Proprotein Convertase Subtilisin/Kexin Type 9 Market Restraints
Table 18. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue by Players (2016-2021) & (US$ Million)
Table 19. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Players (2016-2021)
Table 20. Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 as of 2020)
Table 21. Ranking of Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Companies by Revenue (US$ Million) in 2020
Table 22. Global 5 Largest Players Market Share by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue (CR5 and HHI) & (2016-2021)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Proprotein Convertase Subtilisin/Kexin Type 9 Product Solution and Service
Table 25. Date of Enter into Proprotein Convertase Subtilisin/Kexin Type 9 Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million)
Table 28. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2016-2021)
Table 29. Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 30. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 31. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size Share by Application (2016-2021) & (US$ Million)
Table 32. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Application (2016-2021)
Table 33. Global Proprotein Convertase Subtilisin/Kexin Type 9 Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 34. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 35. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million)
Table 36. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million)
Table 37. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million)
Table 38. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million)
Table 39. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million)
Table 40. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million)
Table 41. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million)
Table 42. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million)
Table 43. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million)
Table 44. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million)
Table 45. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million)
Table 46. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million)
Table 48. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million)
Table 50. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million)
Table 51. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2016-2021) & (US$ Million)
Table 52. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Region (2022-2027) & (US$ Million)
Table 53. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million)
Table 54. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million)
Table 55. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million)
Table 56. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million)
Table 57. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million)
Table 58. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2016-2021) (US$ Million)
Table 60. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Type (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2016-2021) (US$ Million)
Table 62. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Application (2022-2027) & (US$ Million)
Table 63. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2016-2021) & (US$ Million)
Table 64. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size by Country (2022-2027) & (US$ Million)
Table 65. AFFiRiS AG Company Details
Table 66. AFFiRiS AG Business Overview
Table 67. AFFiRiS AG Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 68. AFFiRiS AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 69. AFFiRiS AG Recent Development
Table 70. Betagenon AB Company Details
Table 71. Betagenon AB Business Overview
Table 72. Betagenon AB Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 73. Betagenon AB Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 74. Betagenon AB Recent Development
Table 75. Bioleaders Corp Company Details
Table 76. Bioleaders Corp Business Overview
Table 77. Bioleaders Corp Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 78. Bioleaders Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 79. Bioleaders Corp Recent Development
Table 80. BioLingus AG Company Details
Table 81. BioLingus AG Business Overview
Table 82. BioLingus AG Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 83. BioLingus AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 84. BioLingus AG Recent Development
Table 85. Catabasis Pharmaceuticals Inc Company Details
Table 86. Catabasis Pharmaceuticals Inc Business Overview
Table 87. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 88. Catabasis Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 89. Catabasis Pharmaceuticals Inc Recent Development
Table 90. Dicerna Pharmaceuticals Inc Company Details
Table 91. Dicerna Pharmaceuticals Inc Business Overview
Table 92. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 93. Dicerna Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 94. Dicerna Pharmaceuticals Inc Recent Development
Table 95. Eli Lilly and Co Company Details
Table 96. Eli Lilly and Co Business Overview
Table 97. Eli Lilly and Co Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 98. Eli Lilly and Co Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 99. Eli Lilly and Co Recent Development
Table 100. Ensemble Therapeutics Corp Company Details
Table 101. Ensemble Therapeutics Corp Business Overview
Table 102. Ensemble Therapeutics Corp Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 103. Ensemble Therapeutics Corp Recent Development
Table 104. Kowa Co Ltd Company Details
Table 105. Kowa Co Ltd Business Overview
Table 106. Kowa Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 107. Kowa Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 108. Kowa Co Ltd Recent Development
Table 109. Novartis AG Company Details
Table 110. Novartis AG Business Overview
Table 111. Novartis AG Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 112. Novartis AG Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 113. Novartis AG Recent Development
Table 114. Pfizer Inc Company Details
Table 115. Pfizer Inc Business Overview
Table 116. Pfizer Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 117. Pfizer Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 118. Pfizer Inc Recent Development
Table 119. Regeneron Pharmaceuticals Inc Company Details
Table 120. Regeneron Pharmaceuticals Inc Business Overview
Table 121. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 122. Regeneron Pharmaceuticals Inc Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 123. Regeneron Pharmaceuticals Inc Recent Development
Table 124. Serometrix LLC Company Details
Table 125. Serometrix LLC Business Overview
Table 126. Serometrix LLC Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 127. Serometrix LLC Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 128. Serometrix LLC Recent Development
Table 129. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Details
Table 130. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
Table 131. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 132. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 133. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development
Table 134. The Medicines Company Company Details
Table 135. The Medicines Company Business Overview
Table 136. The Medicines Company Proprotein Convertase Subtilisin/Kexin Type 9 Product
Table 137. The Medicines Company Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021) & (US$ Million)
Table 138. The Medicines Company Recent Development
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type: 2020 VS 2027
Figure 2. SX-PCK9 Features
Figure 3. O-304 Features
Figure 4. K-312 Features
Figure 5. BLSM-201 Features
Figure 6. DCRPCSK-9 Features
Figure 7. Others Features
Figure 8. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application: 2020 VS 2027
Figure 9. Cardiovascular Disease Case Studies
Figure 10. Homozugous Familial Hyperchalesterolemia Case Studies
Figure 11. Liver Disease Case Studies
Figure 12. Metabolic Syndrome Case Studies
Figure 13. Others Case Studies
Figure 14. Proprotein Convertase Subtilisin/Kexin Type 9 Report Years Considered
Figure 15. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 16. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 17. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions: 2020 VS 2027
Figure 18. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Regions (2022-2027)
Figure 19. Global Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Players in 2020
Figure 20. Global Top Proprotein Convertase Subtilisin/Kexin Type 9 Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Proprotein Convertase Subtilisin/Kexin Type 9 as of 2020
Figure 21. The Top 10 and 5 Players Market Share by Proprotein Convertase Subtilisin/Kexin Type 9 Revenue in 2020
Figure 22. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2016-2021)
Figure 23. Global Proprotein Convertase Subtilisin/Kexin Type 9 Revenue Market Share by Type (2022-2027)
Figure 24. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027)
Figure 26. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027)
Figure 27. North America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027)
Figure 28. United States Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Canada Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027)
Figure 32. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027)
Figure 33. Europe Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027)
Figure 34. Germany Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. France Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. U.K. Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Italy Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Russia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Nordic Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027)
Figure 42. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027)
Figure 43. Asia-Pacific Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Region (2016-2027)
Figure 44. China Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Japan Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. South Korea Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Southeast Asia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. India Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Australia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027)
Figure 52. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027)
Figure 53. Latin America Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027)
Figure 54. Mexico Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Brazil Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Type (2016-2027)
Figure 58. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Application (2016-2027)
Figure 59. Middle East & Africa Proprotein Convertase Subtilisin/Kexin Type 9 Market Share by Country (2016-2027)
Figure 60. Turkey Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. Saudi Arabia Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. UAE Proprotein Convertase Subtilisin/Kexin Type 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 63. AFFiRiS AG Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 64. Betagenon AB Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 65. Bioleaders Corp Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 66. BioLingus AG Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 67. Catabasis Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 68. Dicerna Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 69. Eli Lilly and Co Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 70. Ensemble Therapeutics Corp Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 71. Kowa Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 72. Novartis AG Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 73. Pfizer Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 74. Regeneron Pharmaceuticals Inc Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 75. Serometrix LLC Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 76. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 77. The Medicines Company Revenue Growth Rate in Proprotein Convertase Subtilisin/Kexin Type 9 Business (2016-2021)
Figure 78. Bottom-up and Top-down Approaches for This Report
Figure 79. Data Triangulation
Figure 80. Key Executives Interviewed

---